Indian economy, European generics and more... - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Indian economy, European generics and more...

Apr 8, 2008

  • Morgan Stanley (through its Global Economic Forum) has revised India's GDP growth estimates in light of the increasing commodity prices, rising inflation and credit turmoil in the developed world. It has revised the GDP growth estimates to 7.1% from 7.4% for FY09 and to 7.6% from 7.8% for FY10. The firm has cited slowdown in two-wheeler sales, consumer durables production and mortgaging lending as signs that the economy is slowing. While the production growth of consumer goods has slumped to 4.3% during the three months ended January 2008 from the peak of 18.5% in June 2005, two-wheeler sales have been declining year on year for the past 11 months. Growth in fresh mortgage disbursements has remained low at single-digit levels for the last few quarters. Export growth has also been hampered due to the sharp appreciation of the rupee against the dollar.

    As per Morgan Stanley, export growth in rupee terms has weakened to an average of 7.9% over the past six months compared with 23.3% during the 12 months ended March 2007. While the obvious measure in such a scenario would be to reduce interest rates to boost consumption, escalating food prices and a consequent rise in inflation has meant that the RBI is unlikely to soften the interest rates until the inflation is brought down to respectable levels. Indian stockmarkets have also had to bear the brunt of huge selling pressure due to the outflow of FII money as the saga of the global credit crunch painstakingly unravels coupled with the surging inflation back home.

  • Dr.Reddy's acquisition of an Italian generics company last week highlights the fact that the region continues to attract domestic pharma companies despite the intensifying pricing pressure of late (Germany for instance). In the European markets, most of the healthcare costs are borne by the state. Being a heterogeneous market, the growth of generics varies country by country. For instance, while the generic penetration is high in the UK and Germany, it has yet to gain pace in Spain, France and Italy. That said, in many European countries, pharmacies and doctors are being encouraged to prescribe generic products, which can also be gauged by the fact that generics have been growing at a faster clip than the total pharmaceutical market in Europe.

    Pricing trends are different for every country as well. Although the generic share in volume terms for the US is the world's largest, the share in value terms is relatively lower than either the UK or the German market. This is due to the fact that the price difference between generics and branded drugs in Europe is much narrower than that in the US. Also, due to the absence of any 180-day exclusivity period in Europe, prices for generic drugs throughout their life-cycle tend to remain more stable. To put things in perspective, typically in the US, during the 180-day exclusivity period, a generic company prices its products approximately 30% below the price of the branded drug. Once this period concludes and more players launch products, prices erode by as much as 90%. This kind of volatility is not witnessed in the European markets (the latter not providing the 180-day exclusivity), though prices do decline with increasing competition.

Equitymaster requests your view! Post a comment on "Indian economy, European generics and more...". Click here!


More Views on News

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

How to Save Money by Exiting Stocks Before They Fall podcast (Views On News)

Sep 24, 2020

A penny saved is a penny earned. It doesn't matter where you enter. All that matter is where you exit. Watch this video to identify an opportune time to exit your investments and book profits.

ICICI Prudential ESG Fund: Aims for Sustainability (Outside View)

Sep 24, 2020

PersonalFN briefly explains the newly launched fund : ICICI Prudential ESG Fund.

What to Do if there is a Second Wave of the Stock Market Crash (Profit Hunter)

Sep 24, 2020

Here's what I think investors should do in this selloff.

IDFC Mutual Fund Starts Campaign 'SIFI'. Should Buy Into the Idea? (Outside View)

Sep 23, 2020

IDFC Mutual Fund is taking the road less travelled and hence started a campaign SIFI (SIP in Fixed Income) to promote the concept of SIP for its debt funds investors.

More Views on News

Most Popular

India in Crisis

Here we highlight the crisis scenarios that India could face. The worry is that there aren't really any easy solutions in sig...

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 24, 2020 (Close)